KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.85

Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT).

Heather L Gelhorn, Katelyn N Cutts, Brooke Harrow, Christopher Tait, Amanda Saunders, Tsion Fikre, Yipin Han, Nicholas A Zeringo, Michiel Van De Sande, William Tap, Hans Gelderblom, Nicholas Bernthal

Qual Life Res 35(3) 57

PMID41621028
PMCIDPMC12861995
DOI10.1007/s11136-026-04162-7
发表日期2026-02-01
入排依据:While the record is from a randomized Phase III oncology trial with a drug intervention, the reported results do not pertain to a time-to-event efficacy endpoint (e.g., OS, PFS). The endpoints analyzed (PROMIS-PF, active ROM, stiffness) are patient-reported outcomes and functional measures, and the analysis defines responder thresholds for these, which falls under a secondary or methodological analysis, not the primary/key secondary time-to-event analysis required for inclusion.
入排复审未纳入:While the record is from a randomized Phase III oncology trial with a drug intervention, the reported results do not pertain to a time-to-event efficacy endpoint (e.g., OS, PFS). The endpoints analyzed (PROMIS-PF, active ROM, stiffness) are patient-reported outcomes and functional measures, and the analysis defines responder thresholds for these, which falls under a secondary or methodological analysis, not the primary/key secondary time-to-event analysis required for inclusion.
摘要

摘要

BACKGROUND: Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm associated with limited range of motion (ROM), stiffness, joint damage, pain, and reduced physical functioning (PF). The MOTION Phase 3 trial (NCT05059262) was a randomized, placebo-controlled, double-blind study of vimseltinib among patients with TGCT. The objective of the current study was to define meaningful changes in clinical outcome assessments (COAs) measuring active ROM, PF, and stiffness using qualitative and quantitative data from patients in the MOTION trial. METHODS: Embedded exit interviews with patients in MOTION were conducted to explore meaningful changes in Patient Global Impression of Change (PGIC) anchors, active ROM, Patient-Reported Outcomes Measurement Information System (PROMIS)-PF, and Worst Stiffness numeric rating scale (NRS). Anchor- and distribution-based analyses of the MOTION data, informed by the exit interviews, were used to define responder thresholds. RESULTS: In the MOTION trial, 96/123 patients (78%) completed an exit interview. Most considered "minimally improved" responses for each question (PGIC-PF: 67%; PGIC-ROM 73%) as meaningful. Responder estimates ranged from 1.45 to 4.9 (PROMIS-PF), from 6.0 to 14.8 (active ROM), and from - 2.3 to - 0.5 (Stiffness). The cumulative distribution function curves show a clear separation between treatment groups at a wide range of values around the proposed thresholds. CONCLUSIONS: The responder definitions were at least a 3-point improvement for PROMIS-PF, a 10% improvement for active ROM, and a 2-point improvement for the Worst Stiffness NRS. Qualitative interviews facilitate integrating the patient perspective in the selection of anchors and defining meaningful change.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。